Sirimusika Nathapol, Boonyapipat Sathana
Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine, Prince of Songkla University, Hat Yai Songkhla Thailand.
Health Sci Rep. 2022 Jul 20;5(4):e729. doi: 10.1002/hsr2.729. eCollection 2022 Jul.
This study aimed to identify the optimal human chorionic gonadotropin (hCG) ratio in predicting etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in women diagnosed with high-risk gestational trophoblastic neoplasia (GTN) and to compare the chemoresistant disease detection rate by using the optimal hCG ratio and traditional criteria.
Seventy-six women with primary high-risk GTN treated with etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine in a tertiary-care center were included. The hCG ratio was determined by its serum pretreatment level divided by that before each cycle of chemotherapy. The traditional criteria for chemoresistance included plateau or rising of hCG or presence of new metastasis. The optimal hCG ratio was determined using receiver operating characteristics (ROC) curve analysis.
Among the specificities of 90%, 92.5%, and 95%, the 90% specificity yielded the best ROC curve. At 90% specificity, the best area under curve value was at the fourth cycle with 75% sensitivity. The hCG ratio at the fourth cycle was 31.92. Using the ratio at the fourth cycle, chemoresistant disease was detected in six out of eight patients, compared to one in the traditional criteria. When combining the two diagnostic tools, the cumulative detection rate in the fourth cycle was 10/12 (83.3%) of total drug resistance. Among patients who developed drug resistance at the fourth cycle or thereafter, the use of the ratio at the fourth cycle could diagnose chemoresistance approximately two cycles earlier than that with the traditional criteria.
A hCG ratio of <31.9 at the fourth cycle should be considered a high-risk for etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance and may need second-line chemotherapy. The ratio increases the detection rate of resistance to these drugs more than the traditional criteria.
本研究旨在确定在预测高危妊娠滋养细胞肿瘤(GTN)女性对依托泊苷、甲氨蝶呤、放线菌素D、环磷酰胺和长春新碱耐药性方面的最佳人绒毛膜促性腺激素(hCG)比值,并比较使用最佳hCG比值和传统标准检测化疗耐药疾病的比率。
纳入了在一家三级医疗中心接受依托泊苷、甲氨蝶呤、放线菌素D、环磷酰胺和长春新碱治疗的76例原发性高危GTN女性患者。hCG比值通过化疗前血清水平除以每个化疗周期前的水平来确定。化疗耐药的传统标准包括hCG平台期或上升或出现新的转移灶。使用受试者工作特征(ROC)曲线分析来确定最佳hCG比值。
在特异性为90%、92.5%和95%时,90%特异性产生了最佳的ROC曲线。在90%特异性时,曲线下面积最佳值出现在第4周期,敏感性为75%。第4周期的hCG比值为31.92。使用第4周期的比值,8例患者中有6例检测到化疗耐药疾病,而传统标准下为1例。当将两种诊断工具结合使用时,第4周期的累积检测率为总耐药性的10/12(83.3%)。在第4周期或之后出现耐药的患者中,使用第4周期的比值诊断化疗耐药比传统标准大约早两个周期。
第4周期hCG比值<31.9应被视为对依托泊苷、甲氨蝶呤、放线菌素D、环磷酰胺和长春新碱耐药的高危因素,可能需要二线化疗。该比值比传统标准更能提高对这些药物耐药性的检测率。